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217 Relationship between Pseudomonas antibody levels, clinical
wellbeing and the Leeds criteria for infection status
T. Lee2, D. Peckham1, S. Conway1, C. Etherington1. 1Regional Adult CF Unit,
Leeds, United Kingdom; 2Regional Paediatric CF Unit, Leeds, United Kingdom
Introduction: Pseudomonas antibody measurements are a method of monitoring
P. aeruginosa infection status. The Leeds criteria are based on microbiological
culture results from respiratory samples. The aim was to determine if there is any
correlation between serology and microbiology in deﬁning Pseudomonas infection.
Methods: Pseudomonas antibodies were measured using a Genesis diagnostic
ELISA kit and partially puriﬁed lipopolysaccharide antigens. The Leeds criteria
categorises patients as ‘never’ had P. aeruginosa infection, ‘free’ of infection for
at least 12 months, ‘intermittently’ infected or ‘chronically’ infected. Data were
retrieved from all patients (excluding Bcc and post-transplant) attending the Leeds
Paediatric and Adult Units in 2007.
Results: One hundred and twenty six children and 271 adults were categorised as
follows: ‘never’ – paediatrics 10%, adults 17%; ‘intermittent’ – paediatrics 42%,
adults 19%; ‘free’ – paediatrics 39%, adults 6% and ‘chronic’ – paediatrics 9%,
adults 58%. In the ‘never’ group 92% of children and 100% of adults had normal
antibody levels (8U/ml). In the ‘chronic’ group 100% of children and 96% of
adults had raised antibody levels. In children there was a signiﬁcant correlation
between antibody level and age (p = 0.02), but no correlation with weight, height,
or BMI standard deviation scores. In the adults there was a signiﬁcant correlation
between antibody level and both FEV1 and BMI (p< 0.001). Adult FEV1 levels
rose from a median 49% predicted in the ‘chronic’ group to 78% predicted in the
‘never’ group (p< 0.001).
Conclusions: Pseudomonas antibody levels accurately reﬂect the infection status
categories in paediatric and adult populations.
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EPI-hNE4, a speciﬁc inhibitor of human neutrophil elastase (hNE), has been
proposed for treatment of cystic ﬁbrosis (CF) lung disease because it may reduce
hNE-induced lung tissue damage. Interestingly, it has been reported that the
Epithelial Na+ Channel (ENaC), which is responsible for Na+ hyperabsorption
in CF airways, could be activated by trypsin-like serine proteases such as Channel-
Activating Proteases (CAP) expressed by airway epithelial cells or hNE released by
neutrophils. EPI-hNE4 could then be useful in the treatment of CF lung disease by
inhibiting hNE-induced increase in ENaC activity, in addition to its anti-elastolytic
activity.
We evaluated by short-circuit current (Isc) measurements the effects of hNE and
EPI-hNE4 on ENaC activity in primary cultures of human nasal epithelial cells
(HNEC) from control (9) and CF (2) patients. hNE or EPI-hNE4 treatment did
not modify Isc in either normal or CF HNEC. However, hNE increased amiloride-
sensitive Isc in normal or CF HNEC pretreated with aprotinin, an inhibitor of CAP
activity, and this effect was completely abolished in the presence of EPI-hNE4.
These results indicate that hNE can activate in vitro ENaC and Na+ absorption in
CF and normal HNEC, but that this effect is only seen after blockade of endogenous
CAP activity. Thus, the pathophysiological importance of hNE-induced activation
of ENaC in CF airways in vivo most likely depends on the level of CAP expression
and activity in airway epithelial cells. Finally, the potent inhibitory effect of EPI-
hNE4 on hNE-mediated ENaC activation observed in our experiments suggests
that EPI-hNE4 could be of interest to reduce ENaC hyperactivity in CF airways in
association with an inhibitor of CAP activity.
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CF patients are exposed to a lifelong and large burden of antibiotics. The goal of
this project was to analyse the characteristics of allergic (immunopathologic) and
non-immunopathologic (toxic) reactions in CF.
We analysed all adverse drug reactions to antibiotics, which were noted routinely
on a side-effect-sheet in the patients charts, during 2002 to 2004 in 379 CF patients
attending the unit. In addition, we sent a questionnaire to all patients and compared
the results with those from the charts.
251 questionnaires were returned and could be utilized, yielding a response rate
of 66%. Of the 251 patients with questionnaires and chart records available,
80 experienced 187 reactions, of which 63 were immunopathologic, the others
were classiﬁed as toxic. To specify the immunopathologic reactions further, these
were divided into deﬁnitive (reproducible on exposition; n = 16), very likely (no re-
exposition tried, but no other explanation for the symptoms observed, n = 41). Of
the immunopathologic reactions 47 (75.6%) were limited to the skin, and 4 (6.3%)
to the skin and the respiratory tract. Shock (n = 2) or fever were noted only with iv
treatment. A reduced frequency of immunopathologic reactions during iv treatment
with cephalosporins was noted in patients with continuous oral cephalosporins
(intake over 50%/year) treatment, in contrast to sporadic treatment (less than
50%/year).
It is important to identify immunopathologic reactions. This helps to main-
tain the repertoire of drugs available for a speciﬁc patient. Intermittent intake
of cephalosporins was associated with more reported allergic reactions to iv-
cephalosporins than continuous treatment.
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Not only basic CFTR mutation, but also other factors are involved in large pheno-
typic variance in CF, especially in respiratory tract. Due to the role of mannose-
binding lectin (MBL) in innate immune mechanism and reported association of
MBL deﬁciency and susceptibility to various infections, we therefore investigated
possible inﬂuence of MBL2 gene polymorphism on the phenotype of CF.
Material and Methods: MBL2 gene promotor polymorphisms (at position −550
and −221) and mutations in the gene coding region (codons 52, 54, 57 within
exon 1) were determined in 168 CF patients and 255 controls by multiplex PCR.
MBL concentrations in serum (168 CF patients, 80 controls) and BAL supernatants
(45 CF, 100 controls) were measured using ELISA. Corresponding MBL2 gene
polymorphisms and concentrations were compared with lung function (FEV1) and
clinical status.
Results: MBL2 gene polymorphisms strongly correlate with MBL serum and BAL
concentrations. CF patients bearing MBL genotype associated with low MBL
levels tended to have lower MBL serum levels compared with healthy controls
with the same MBL genotype. These patients with genetically determined low
MBL production presented with worse lung function, however, they were able to
produce high levels of this lectin during acute exacerbation of an infection. MBL
concentrations in BAL were lower than in serum (p< 0.01).
Conclusions: Independently of the MBL genetic pattern, CF patients differ widely
in mainly respiratory phenotype. Severe lung function deterioration is caused by
concurrence between CFTR mutation, many other modiﬁer genes (not just one) and
enviromental inﬂuences.
Supported by: IGA NR8458−5 and VZ 64203.
